Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving seq...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Prachi, Klotz, Jeffrey, Dunavin, Neil, Lu, Kit, Koklanaris, Eleftheria, Draper, Debbie, Superata, Jeanine, Chinian, Fariba, Yu, Quan, Keyvanfar, Keyvan, Wong, Susan, Muranski, Pawel, Barrett, A. John, Ito, Sawa, Battiwalla, Minoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402630/
https://www.ncbi.nlm.nih.gov/pubmed/28462085
http://dx.doi.org/10.1016/j.lrr.2017.04.003
Descripción
Sumario:Patients with high risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) are commonly older with multiple co-morbidities, rendering them unsuitable for intensive induction chemotherapy or transplantation. We report preliminary cellular immune profiling of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results highlight the potential of immune profiling for monitoring immune-modifying agents in high risk MDS and AML.

Ejemplares similares